Answers are grounded in this paper and cite their sources.
Measles outbreaks continue to occur in Uganda despite measles-rubella (MR) vaccination. On 24 June 2025, Kamwenge District, a refugee-hosting area, reported three laboratory-confirmed measles cases. We investigated the outbreak to determine its magnitude, identify risk factors, and estimate vaccine effectiveness (VE), and vaccination coverage (VC). A suspected case was fever and generalized maculopapular rash with ≥ 1 of cough, coryza, or conjunctivitis among Kamwenge residents from 1 February to 7 July 2025; a confirmed case had measles-specific IgM. Cases were identified through health-facility records and community searches. We calculated attack rates (AR), conducted environmental assessments, and performed an age-matched case-control study using neighborhood controls. Conditional logistic regression estimated adjusted odds ratios (aORs). VE was calculated as (1−OR_ M−H )×100; VC was the proportion of vaccinated eligible controls. We identified 109 cases (3 confirmed, 106 suspected); no deaths occurred. Of the cases, 48.6% were refugees. Overall AR was 3.2/10,000, highest among children aged 9–17 months (30.8/10,000) and refugees (13.3/10,000). Among 73 cases and 167 controls, attending a place of worship was associated with infection (aOR = 11.1; 95% CI 3.5–35.1), while MR1 (aOR = 0.3; 95% CI 0.1–0.7) and MR2 (aOR = 0.05; 95% CI 0.01–0.3) were protective. VE was 93% for MR1 and 95% for MR2. Coverage among eligible controls was 67% for MR1 and 36% for MR2. A prolonged outbreak occurred amid low MR coverage and high-contact social mixing. Strengthening routine two-dose vaccination, targeted vaccination in refugee-hosting communities, and prompt isolation of suspected cases may help prevent future outbreaks.
No takes yet. Share an insight, caveat, or question.
Matovu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: